Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    Menu

    Sunobinop

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sunobinop Ph 1B Data in Interstitial Cystitis/Pain Syndrome Out
    Sunobinop Ph 1B Data in Interstitial Cystitis/Pain Syndrome Out

    09 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250908639413/en/Results-From-Sunobinop-Phase-1B-Study-in-Patients-With-Interstitial-CystitisBladder-Pain-Syndrome-Announced

    BUSINESSWIRE
    09 Sep 2025
    Share Share
    Imbrium Therapeutics Achieves Last Patient Last Visit in Clinical Trial
    Imbrium Therapeutics Achieves Last Patient Last Visit in Clinical Trial

    11 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250311007864/en

    BUSINESSWIRE
    11 Mar 2025
    Share Share
    Imbrium Phase 1b Data For Sunobinop In Overactive Bladder Syndrome
    Imbrium Phase 1b Data For Sunobinop In Overactive Bladder Syndrome

    07 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250107207362/en

    BUSINESSWIRE
    07 Jan 2025
    Share Share